FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 	,	 -	

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average but	urden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kewalramani Reshma</u>					V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								heck all app	licable) tor	,		suer wner specify	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS						3. Date of Earliest Transaction (Month/Day/Year) 05/24/2024								X below			below)	эрсспу	
INCORPORATED 50 NORTHERN AVENUE					4. l	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) BOSTON MA 02210					Form filed by More than One Reporti Person										orting				
(City) (State) (Zip)				Ru	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I - No	n-Deriv	ative	Sec	curit	ies Ac	quired	, Dis	sposed o	of, or Be	neficia	lly Owne	d				
D:			Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code	Transaction Disposed Code (Instr.		ties Acquired (A) o d Of (D) (Instr. 3, 4		Benefi Owned	ties cially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price		ed ction(s) 3 and 4)			(Instr. 4)		
Common Stock 05/24/2					/2024	2024		M		1,565	A	\$187	53 122,939			D			
Common Stock 05/24/2				/2024	2024		S ⁽¹⁾		1,565	D	\$45	7 12	1,374		D				
		Т	able II -								osed of converti			y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	4. Transa Code (8)		n of		Expiration	6. Date Exercisabl Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	Own Forn Direc or In (I) (Ir	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Number of Shares						
Stock Option (Right to	\$187.53	05/24/2024			M			1,565	(2)		02/05/2029	Common Stock	1,565	\$0	0		D		

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Kewalramani's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1,\ which\ was\ entered\ into\ on\ 02/07/2024.$
- 2. Fully vested.

Remarks:

/s/ Christiana Stevenson, 05/29/2024 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.